| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dialysis |
* Department of Renal Medicine, King’s College Hospital, London, United Kingdom; Christchurch Clinical Studies Trust, Christchurch, New Zealand; Charles University Medical School, Pilsen, Czech Republic; and F. Hoffmann-La Roche Ltd., Basel, Switzerland
Address correspondence to: Dr. Iain C. Macdougall, Department of Renal Medicine, King’s College Hospital, London, SE5 9RS, UK. Phone: +44-207-346-6234; Fax: +44-207-346-6472; E-mail: iain.macdougall{at}kingsch.nhs.uk
Continuous Erythropoietin Receptor Activator (C.E.R.A.) is a new agent that is in development for the treatment of anemia with extended administration intervals in patients who have chronic kidney disease (CKD), both those on and those not on dialysis. This was an open-label, randomized, multicenter, two-period, crossover study in erythropoiesis-stimulating agentnaïve patients who had CKD and anemia and were receiving peritoneal dialysis. After a 1-wk run-in period, 16 patients were randomly assigned to receive a single administration of intravenous C.E.R.A. 0.4 µg/kg (n = 8) or subcutaneous C.E.R.A. 0.8 µg/kg (n = 8). Six weeks after the first administration of C.E.R.A. (4-wk assessment, 2-wk washout), the route of administration was switched so that all patients received single administrations of both intravenous C.E.R.A. 0.4 µg/kg and subcutaneous C.E.R.A. 0.8 µg/kg. C.E.R.A. had a prolonged and comparable half-life after intravenous (mean 134 h) and subcutaneous (mean 139 h) administration. Reticulocyte counts peaked at a median of 8 d after intravenous and subcutaneous administration with no difference in the time course between administration routes. This resulted in similar mean values for the area under the reticulocyte count-time curve (1191 x 109 and 1193 x 109·d per L, respectively) and the maximum absolute increase in reticulocyte counts (36 x 109 and 41 x 109/L, respectively). C.E.R.A. has a prolonged and comparable half-life after intravenous or subcutaneous injection, suggesting that extended administration intervals may be feasible in patients with CKD.
This article has been cited by other articles:
|
|
 |
|
  B. Canaud, G. Mingardi, J. Braun, P. Aljama, P. G. Kerr, F. Locatelli, G. Villa, B. V. Vlem, A. W. McMahon, C. Kerloeguen, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study Nephrol. Dial. Transplant., July 31, 2008; (2008) gfn320v4. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Walker Erythropoietin Stimulating Agents and Epoetin Alfa Revisited: What's Really Relevant? Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 935 - 937. [Full Text] [PDF]
|
|
|
|
|
|
I. C. Macdougall, R. Walker, R. Provenzano, F. de Alvaro, H. R. Locay, P. C. Nader, F. Locatelli, F. C. Dougherty, U. Beyer, and on behalf of the ARCTOS study investigators C.E.R.A. Corrects Anemia in Patients with Chronic Kidney Disease not on Dialysis: Results of a Randomized Clinical Trial Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 337 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Macdougall Novel Erythropoiesis-Stimulating Agents: A New Era in Anemia Management Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 200 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fishbane, A. Pannier, X. Liogier, P. Jordan, F. C. Dougherty, and B. Reigner Pharmacokinetic and Pharmacodynamic Properties of Methoxy Polyethylene Glycol-Epoetin Beta Are Unaffected by the Site of Subcutaneous Administration J. Clin. Pharmacol., November 1, 2007; 47(11): 1390 - 1397. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
